Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.
1 report, 1 independent
Updated Sep 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Eli Lilly referred entities to the FDA regarding the GLP-1 market on August 24, 2026.
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- Novo Nordisk expanded its pediatric label franchise on September 15, 2026.
- Novo Nordisk's Wegovy rollout is planned for Germany as GLP-1 therapies shift consumer priorities.